BEIJING/NEW YORK, Dec 8 (Reuters) - China's shift from tough COVID policies, with its promise of driving an economic recovery next year, will instead likely depress growth over the next few months as infections surge, bringing a rebound only later in the year, economists said.
There are already signs of revived demand for travel and other services, but China's fragile healthcare system and low vaccination rates have left it ill-prepared for a big wave of infections, which could spark labour shortages and make wary consumers even more skittish.
Some economists have lowered growth forecasts for early next year for the world's second-largest economy, continuing the grim growth numbers this year that were among the worst of the past half-century.
And while longer-term confidence about the recovery remains unshaken, a reopening of the economy could also trigger inflation, which has so far remained relatively tame in China despite surging prices in other major economies.
"Compared with other developed countries, medical resources in China are somewhat insufficient," said Nie Wen, a Shanghai-based economist at Hwabao Trust, who has cut his China growth forecast for the first quarter to 3.5%-4% from 5% previously.
He cited a particular risk of COVID outbreaks when China celebrates the Lunar New Year holiday in January, a popular time for travel among the country's 1.4 billion people.
China's economy grew just 3% in the first three quarters of this year, but an annual meeting next week of top policymakers is expected to aim higher: government advisers told Reuters last month they would recommend 2023 growth targets ranging from 4.5% to 5.5%, while a central bank adviser said last month that China should set a target no lower than 5%.
This year's depressed growth, while due partly to a domestic property market slump and the global economic slowdown, has also been blamed widely on China's harsh COVID-related restrictions.
Lockdowns and quarantines have disrupted supply chains and depressed consumer spending, and eventually triggered widespread protests that spurred the recent policy shift.
With China likely facing waves of COVID infections after the relaxations, the benefits of reopening are expected to arrive with a significant delay.
"Given the accelerated reopening timeline, we believe growth may stay subpar near term," Morgan Stanley said after the announcement of the latest easing measures.
The bank's analysts expect growth to improve modestly but remain subpar in the spring, with "a more meaningful rebound" in the second half of the year and 5% growth for the full year.
HSBC said in a research note that it expected growth above 5% in 2023, citing the relaxed anti-COVID measures and supportive fiscal and monetary policies.
Economists and analysts were confident that, overall, the reopening was more positive for growth.
"Lockdowns mean people can't travel, people can't consume, can't work," said Rich Nuzum, global chief investment strategist at Mercer.
"It's not humane to say it that way, but the GDP impact of lockdowns is a lot bigger than the GDP impact of letting the virus run."
Lurking among the prospects for China's reopening, however, is a potential surge in inflation, which could hit the global economy as well as China itself.
"The potential reopening could bring inflationary challenges to China, with a surge in demand, especially the accelerating household consumption, and short-term disruption to labour supply, production and supply chains amid an inevitable exit wave of new cases," said Bruce Pang, chief economist at Jones Lang Lasalle.
A report by Eastspring Investments warned that this could have implications as well for the inflation battle by the U.S. Federal Reserve and other major central banks.
"A disorderly reopening and a rise in inflation as the economy rebounds would be key risks for China," it said.
"Meanwhile, high energy prices which have been another inflation driver will likely face more upward pressure especially as China begins to reopen, and this could prolong central banks' battle against inflation."
Our Standards: The Thomson Reuters Trust Principles.